Anlon Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026, considered at the Board Meeting held on 29th May, 2026.
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anlon Healthcare Limited reported strong full-year results for FY2025-26. Standalone revenue from operations grew 46.7% to Rs. 17,649.87 Lacs from Rs. 12,028.66 Lacs in the previous year. Profit after tax (standalone) increased 35.5% to Rs. 2,780.82 Lacs from Rs. 2,051.79 Lacs, with consolidated PAT at Rs. 2,908.81 Lacs. Earnings per share improved to Rs. 5.93 from Rs. 5.15. EBITDA margin showed slight compression of 0.33 percentage points to 26.17%. Total equity stood at Rs. 20,977.27 Lacs (standalone). The company listed on NSE and BSE in September 2025. Auditors RVD & Co issued an unmodified (clean) opinion on both standalone and consolidated financial statements. Working capital increased significantly with inventories rising to Rs. 7,558.95 Lacs and trade receivables to Rs. 341.29 Lacs.
Strong revenue and PAT growth indicate robust business performance. The clean audit opinion with no going concern issues supports financial stability. Margin compression warrants monitoring. The working capital buildup may impact near-term cash flow.